Notice NOT-NS-21-068 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-032 from the NIH Guide for Grants and Contracts

£32,557: Animal and Plant Health Agency: The Animal and Plant Health Agency (APHA) is an executive agency of the Department for Environment, Food & Rural..... New Haw, Southeast, Surrey

Funding Opportunity RFA-RM-21-014 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) solicits applications for the continued development of the Gabriella Miller Kids First Pediatric Data Resource Center (DRC), which consists of the following components: a Data Resource Core, a Data Coordination Core, and an Administrative and Outreach Core. The goal of the cloud-based Data Resource is to accelerate discovery of genetic etiology and shared biologic pathways within and across childhood cancers and structural birth defects by facilitating access to and querying of annotated genomic sequence and phenotypic data from cohorts of patients with these conditions. The Data Resource Core will continue to develop the Data Resource, which serves as an indispensable research resource where genomic and phenotypic data can be aggregated, accessed, analyzed, and shared within and across the childhood cancer and structural birth defects research communities as well as the broader scientific community. The Data Coordination Core will work with Kids First investigators and sequencing centers to facilitate data collection, harmonization, and sharing. The Administrative and Outreach Core will oversee administrative activities, work closely with the NIH Kids First Working Group, and provide outreach and education to the research community on using the Data Resource.

Notice NOT-OD-21-175 from the NIH Guide for Grants and Contracts

The position requires extensive interaction with both bioinformatics and data sciences groups which would require the ability to develop a strong, collaborative…
From IntelliGen Technologies - Mon, 23 Aug 2021 18:23:22 GMT - View all Waunakee, WI jobs

Competitive Salary: F. Hoffmann-La Roche AG: The Immunology Incubator is an innovative interface between Roche Pharma Research and Early Development (pRED) and the next generation of academic le Switzerland (CH)

Notice NOT-AG-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-174 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-22-007 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Networks Program, hereafter termed ACE Networks. Each ACE Network will consist of a multi-site project focusing on a specific topic of research for R01 support through this FOA. Each ACE Network will submit one R01 application that includes sub-awards to the collaborating sites. A companion FOA (RFA-HD-22-008) invites applications for ACE Centers supported by the P50 mechanism.

Funding Opportunity RFA-HD-22-008 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Centers Program, hereafter termed ACE Centers. The P50 mechanism allows for integrative, multi-disciplinary, coordinated programs of research that demonstrate cohesion and synergy across research projects and cores. A companion FOA (RFA-HD-22-007) invites applications for ACE Networks supported by the R01 mechanism.

Notice NOT-MH-21-330 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: ELIXIR is seeking an experienced data scientist to coordinate and organise technical architecture and complex projects within the dynamic and internat Hinxton, Cambridgeshire, England

Funding Opportunity PAR-21-282 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and effectivenesting, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the FDA or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech

Funding Opportunity RFA-AA-21-016 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.

Funding Opportunity RFA-AA-21-017 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.

Funding Opportunity PAR-21-315 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website.

Funding Opportunity PAR-21-314 from the NIH Guide for Grants and Contracts. The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish incubator hubs to provide medical device developers (innovators) with resources to support development of human-grade prototypes. The FOA intends to utilize the U54 activity code and is expected to be published in Summer 2021 with an expected application due date in Fall 2021. Incubator hubs will coordinate and manage resources for the Blueprint MedTech program, working as a consortium to provide: (1) infrastructure for identifying the most promising technologies, (2) the distribution of sub-award funding for innovators and resources to support product definition (e.g., needs assessment, product design, prototype development), and (3) access to relevant expertise (e.g., scientific, design, business development, and project management). Details of the planned program are provided below. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications and meaningful collaborations. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published FOAs.

Funding Opportunity PAR-21-313 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and participating Institutes and Centers. New investigators at the time of award under this FOA will have/have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Funding Opportunity PAR-21-306 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award (R50) is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for career continuity.